The treatment of lentigo leukemia with myelofibrosis includes drug therapy and allogeneic stem cell transplantation. 1.Lentigo leukemia is a malignant myeloproliferative neoplasm occurring in multifunctional hematopoietic stem cells and is treated as follows: (1) Tyrosine kinase inhibitor: it is the drug of choice, such as imatinib and nilotinib. (2) Interferon therapy: such as tyrosine kinase inhibitor resistant, intolerant and unsuitable patients, can be considered. (3) Hydroxyurea therapy: fast-acting, can transiently control the white blood cell count and reduce the tumor load. (4) Allogeneic stem cell transplantation: the only curative modality, but transplantation is associated with difficulties in finding suitable donors and transplantation-related problems and a higher risk of death. 2. Myelofibrosis is a chronic myeloid tumor originating from mutations in multipotential hematopoietic stem cells. Treatment is as follows: (1) Androgen therapy: to make some of the severe anemia symptoms improve, such as danazol. (2) Glucocorticoid therapy: used when there is hemolytic anemia, such as prednisone. (3) Targeted drugs: BTK inhibitors have been used in myelofibrosis treatment. If the diagnosis of chronic leukemia with myelofibrosis is confirmed, it is recommended to go to the hospital in a timely manner, under the guidance of the doctor for standardized treatment, the above drugs should not be taken on their own, in order to avoid adverse reactions.